It is now available to order from The Care Pharmacy following a free online consultation and prescriber approval
Ro prioritizes transparency by providing the price for each medication on its website, along with details on its safety and possible side effects
Belardo explains
Protocol number: RP1-104-IGNYTE-3 A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3] Protocol number: RP2-202-NCT06581406 A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Nave Adult Patients with Metastatic Uveal Melanoma Protocol number: RPL554-NCFB-220 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Ensifentrine in Subjects with Non-Cystic Fibrosis Bronchiectasis Protocol number: RPNI Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation: A Randomized, Prospective Study Protocol number: RRTCR1-LGGAIM1 Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters AIM 1 Protocol number: RRTCR1-LGGAIM2 Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters AIM 2 Protocol number: RT234-PAH-CL202 A Phase 2b, Open-label, Single Dose Study to Evaluated the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH) Protocol number: RYZ101-301 Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1) Protocol number: S2209-NCT05561387 S2209: A PHASE III RANDOMIZED TRIAL FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS CONSIDERED FRAIL OR IN A SUBSET OF INTERMEDIATE FIT COMPARING UPFRONT THREE-DRUG INDUCTION REGIMENS FOLLOWED BY DOUBLE- OR SINGLE-AGENT MAINTENANCE
